Class 3: Potassium Channel Blockers – Antiarrhythmic Drugs

The main role of antiarrhythmic agents is to prevent the occurrence of arrhythmia and, in the case of those patients in which abnormal rhythm has occurred; it helps in the termination of the arrhythmia. Antiarrhythmics are classified in various types by means of many classifications. The Vaughan-Williams classification is one of the widely accepted among those. Class 3 drugs constitute potassium channel blockers. These will be discussed in this article.

Antiarrhythmic Drugs

Antiarrhythmic drugs can be classified according to their mechanism of action. Therefore, the Vaughan-Williams classification lists five groups:

**Class 1** constitutes the sodium channel blockers and is, in turn, divided into three groups (1A, 1B and 1C), based on the action potential duration, the amount of reduction of the phase 0 slope, and effective refractory period.

**Class 2** drugs constitute of beta blockers.

**Class 3** are potassium channel blockers – amiodarone, dronedarone, bretylium, sotalol, ibutilide and dofetilide. These will be discussed in this article.
**Calcium channel blockers** are classified as **class 4** and **miscellaneous drugs** are **class 5**.

**Mechanism of Action of Potassium Channel Blockers**

Potassium is the chief ion in the **repolarization**. At the end of depolarization, potassium efflux occurs following the opening of the potassium channels. These drugs bind to and block the potassium channels that are responsible for phase 3 repolarization. Therefore, blocking these channels slows (delays) repolarization, which leads to an increase in action potential duration and an increase in the effective refractory period (ERP).

![Image of membrane with ions and currents](Image created by Lecturio)

This group of drugs binds to the channel which is responsible for the potassium movement and blocks it (**rapid component of the delayed rectifier current (IKr)**). Once the blocking has happened, the refractory period increases.

The refractory period is the time interval in which no stimulus can induce the occurrence of a new action potential, which in turn leads to no propagation of myocardial contraction. The refractory period is further divided into two types, named **relative and absolute refractory period**. The potassium channel blocker increases the duration of the absolute refractory period of both the atria and the ventricles; thus the action potential widens, slowing the frequency of depolarizations.

*“Group 3 Antiarrhythmics. Effective refractory period” Image created by Lecturio*
One of the important mechanisms which cause continuous tachyarrhythmia is the **circuit of excitatory impulse** which excites the ventricle again and again. Potassium channel blockers block these re-entry circuits by means of inhibition of the effect of the impulse by making the tissue refractory at the time the impulse arrives.

It is worth to note that **amiodarone** is said to have an **electrophysiological property** in addition to its potassium channel blocking property. It also acts as a sodium channel blocker, anti-adrenergic and L-type calcium channel blocker (note that these are the property of the class 1, class 3 and class 4 drugs according to the Vaughan-Williams classification).

All these are the reasons behind the therapeutic efficacy of amiodarone.

**Amiodarone**

Amiodarone has shown efficacy in the management of both supraventricular and ventricular **arrhythmias**, but its approved usage is limited by its long time of onset of action and its array of side effects.

**Pros & Cons and the Main Indication of Amiodarone**

**Atrial Arrhythmia**
Amiodarone, both IV and oral, is given as a maintenance treatment, restoration treatment and for the prophylaxis of atrial fibrillation, ventricular tachycardia, including ventricular fibrillation; atrial fibrillation and atrial flutter (off-label use)

**Maintenance Treatment**

Though not FDA approved, oral amiodarone is widely used for the maintenance treatment of sinus arrhythmia in patients with atrial fibrillation. Though oral amiodarone is not a recommended therapy for the cardioversion in active atrial fibrillation (this is because the oral amiodarone takes time for its action to occur), it can be given in some cases.

Oral amiodarone is also used for the prevention of paroxysmal atrial fibrillation. Intravenous amiodarone is used mainly in severe cases and the indications include the maintenance of sinus rhythm in AF patients who are unstable hemodynamically.

**Restoration Treatment**

Though convincing evidence is not available, amiodarone is used for the restoration of sinus rhythm in patients with unstable atrial fibrillation. Critically ill patients forms the main treatment group (in this group of patients, ventricular fibrillation occurs along with atrial fibrillation contributing to the unstability).

**Given as a Prophylaxis**

Amiodarone (both oral and intravenous) is used as a prophylaxis before cardiac surgery in order to prevent atrial fibrillation in high-risk patients. The drug is also given to those patients who have high risk of atrial fibrillation during electrical cardioversion. The treatment, in this case, should start long before (2-6 weeks before the planned cardioversion).

**Ventricular Arrhythmia**

Oral amiodarone has shown efficacy in preventing the occurrence of VT in patients with myocardial infarction and congestive heart failure.

**Ventricular Refractory Arrhythmia and Pulseless VT and VF (Sudden Cardiac Death)**
A recent RCT (2016) published in NEJM, where lidocaine, amiodarone and placebo are compared for pulseless VT or VF in those patients in whom initial defibrillation or vasopressor therapy has shown refraction, has shown that there is no difference in survival (primary outcome of the trial).

There occurred a mild non-significant survival benefit on both the drug treatment groups when compared to the placebo in the bystander-witnessed arrest.

It has to be noted that the two most famous trials, namely the ALIVE trial and the ARREST trial, where amiodarone has been compared with lidocaine in sudden cardiac arrest patients having persistent VF after defibrillation, have shown only improvement in the rate of hospital admissions after the arrest, but not survival. In the ARREST trial, amiodarone was associated with more side effects. Survival to hospital discharge and survival with favorable neurologic outcome, however, was not improved by amiodarone compared with placebo or amiodarone compared with lidocaine, although these studies were not powered for survival or favorable neurologic outcome.

Based on the above evidence, amiodarone is suggested by the AHA guidelines as the first line drug for the treatment during sudden cardiac arrest, rather than lidocaine (this is also confirmed by a Cochrane study): “Amiodarone may be therefore considered for VF/pVT that is unresponsive to CPR, defibrillation, and a vasopressor therapy. (Class IIb, LOE B-R)”.

It should, however, be remembered that the first line of therapy to be given to a patient with VF or VT related sudden cardiac arrest is an effective CPR along with defibrillation, if indicated.

Defibrillation (implantable cardioverter-defibrillators (ICDs) after successful administration with automatic external defibrillators, or AED’s) is the only proven effective treatment of the VF and VT. The administration of the antiarrhythmic drugs, like amiodarone and lidocaine, is only after effective CPR and successful defibrillation.

Pharmacokinetics of Amiodarone

Oral amiodarone is lipophilic and it takes time to attain the intended concentration in the blood (due to the increase in the volume of distribution seen with the lipophilic drugs).

Amiodarone is an inhibitor of CYP3A4, so the interaction concerned with the drugs which are metabolized by the CYP3A4 needs to be taken care of.

The drug also significantly interacts with warfarin, this requiring dose modifications. In addition to this, the alteration in thyroid function caused by amiodarone further affects
warfarin concentration.

**Adverse and Side Effects Related to Amiodarone**

Though amiodarone is almost a wonder drug in arrhythmias, it has gone into disfavor mainly because of its side effect profile. That's the reason why it is used mainly in **refractory ventricular arrhythmia**, rather than the atrial fibrillation, even if it has a high efficacy in AF.

The side effects are mainly seen with long term therapy, rather than short term intravenous therapy.

The exposure to low-dose oral amiodarone for a long duration has the following odds of developing side effects when compared to placebo, namely 4.2%, 3.4%, 2.0% for thyroid, ocular and skin/neurological/pulmonary toxicity respectively. The above data is according to a meta-analysis on the side effect profile.

**Mnemonic: Amiodarone Side-Effects + Toxicity are a “BITCH”**

- Bradycardia/Blue man
- Interstitial Lung Disease
- Thyroid (hyper and hypo)
- Corneal (ocular)/Cutaneous (skin)
- Hepatic/Hypotension when IV (due to solvents)

The side effect profile of intravenous amiodarone is different. The most common adverse effect with intravenous preparations is **hypotension**, and this is significantly reduced by the latest pharmaceutical preparation (containing aqueous base).

![Image: “Prolonged QT Interval; Torsades de pointes (TdP).” by Jer5150 - Own Work. License: CC BY-SA 3.0](https://example.com/image.png)

It should be noted that although amiodarone is more potent compared to other groups of antiarrhythmic agents, it has fewer pro-arrhythmic effects. When the arrhythmia occurs with amiodarone, the most common seen is the **Torsades de pointes**. The risk increases in women and with the presence of other co-electrolyte abnormalities.

The most common cause of death with a patient on amiodarone therapy is **pulmonary toxicity** with the most important predictor being the cumulative dose given. The most common type of pulmonary toxicity involves **chronic interstitial pneumonitis** and the presence of an increased number of foamy macrophages in the lungs’ air spaces.

This warrants immediate stoppage of the drug and treatment with corticosteroids.
The **other side effects** include gastrointestinal disturbances, liver function abnormalities, bradycardia, asystole, localized phlebitis, non-productive cough, acute respiratory distress syndrome (rare), and bluish-slate gray discoloration of the skin (see above), along with the presence of photosensitivity.

In addition, **neurological toxicity**, like peripheral neuropathy, paresthesia, abnormal walking, and alteration in the blood lipid levels are seen. **Hypothyroidism** or **hyperthyroidism**, are not uncommon.

**Reversible corneal deposits** can be seen in patients treated with amiodarone. As the vision remains still intact, the corneal micro-deposits are not an indication for stopping the amiodarone therapy. The mechanism behind the formation is due to the secretion of amiodarone through the lacrimal gland. There is also a **risk of optic nerve injury** causing blindness.

Regarding the liver function abnormality, it is recommended to monitor the liver function every 6 months. The drug needs to be discontinued if the elevation in the liver enzymes is more than the two-fold.

The two proposed mechanisms are **phospholipidosis** (the phospholipids of the liver interact with the amiodarone) and **metabolic idiosyncrasy** (potential in some individual to produce more toxic metabolites from a given drug).

**Reverse Use Dependence**

Except for amiodarone, all the other members of class 3 antiarrhythmic drugs, like sotalol, exert the property of reverse use dependence. This means that, as the heart rate decreases, there occurs an increased risk of **prolongation of QT interval**. This increases the risk of **Torsades de pointes** and also decreases the efficacy of the drug.

There are also other proposed mechanisms on why the incidence of Torsades de pointes is less with amiodarone; they include the properties of amiodarone like concurrent inhibition of L type calcium channels, but the mechanism is not fully understood.

**Dronedarone**

The mechanism of action is the same as the whole group. It acts on all the 4 channels (sodium, potassium, calcium and the alpha 1 and it antagonizes all these receptors).
**Indication**

The drug is used in patients with persistent AF who need to reduce the risk of hospitalization for AF (note, in these patients the rhythm can still be reverted back). The drug is also used for the treatment of AF in patients of Hypertrophic Obstructive Cardiomyopathy (HOCM).

**Contraindications**

The drug is contraindicated in patients with NYHA class 4 symptomatic heart failure. Dronedarone is also shown to increase the risk of death in those patients with refractory atrial fibrillation.

**Adverse Effect**

**Prolonged QT** is the most common adverse effect seen with this drug. Along with that, there occurs an increase in the renal parameters, dermatologic manifestation like allergic dermatitis, neuromuscular weakness and bradycardia.

**Sotalol**

![Sotalol Chemical Structure](https://upload.wikimedia.org/wikipedia/commons/thumb/8/8a/Sotalol.png/220px-Sotalol.png)

**Mechanism**

The drug is a **racemic mixture of d and l isomers**. The concentrations of both isomers is approx. 1:1 and have different mechanisms of action.

The d isomer has the blocking property of delayed potassium channel-induced depolarization (similar to other drugs in the class 3 antiarrhythmics); the l isomer in addition to this property also has a beta blocking property.

It should be noted that although the name sotalol sounds like a beta blocker, it is classified under the class 3 anti-arrhythmic agent based on its functional properties.

**Indication**

Oral sotalol is used for the treatment of sustained VT which is potentially life threatening and in sinus rhythm patients at risk of developing **atrial fibrillation**.

**Adverse Effects**

The drug should not be given in patients with **congenital QT prolongation** and its common side effects are a decrease in heart rate, difficulty breathing, a dizzy feeling,
fatigue and lack of energy.

References


Legal Note: Unless otherwise stated, all rights reserved by Lecturio GmbH. For further legal regulations see our legal information page.